Disadvantaged subgroups of metastatic non-small cell lung cancer (mNSCLC) patients treated with nivolumab.

Rossi, S; Finocchiaro, G; Toschi, L; Santoro, A

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (15):